Waverley Pharma Inc.
WAVE.V
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.08M | 891.40K | 612.70K | 340.00K | 52.20K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.08M | 891.40K | 612.70K | 340.00K | 52.20K |
| Cost of Revenue | 650.70K | 506.10K | 360.30K | 186.80K | 77.40K |
| Gross Profit | 424.40K | 385.20K | 252.30K | 153.20K | -25.20K |
| SG&A Expenses | 617.10K | 492.10K | 467.30K | 474.00K | 520.50K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.29M | 1.14M | 1.09M | 971.30K | 940.80K |
| Operating Income | -216.60K | -247.70K | -477.50K | -631.20K | -888.50K |
| Income Before Tax | -263.40K | -291.90K | -523.80K | -694.60K | -1.63M |
| Income Tax Expenses | 1.20K | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.26 | -0.29 | -0.52 | -0.69 | -1.63 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -264.60K | -291.90K | -523.80K | -694.60K | -1.63M |
| EBIT | -216.60K | -247.70K | -477.50K | -631.20K | -888.50K |
| EBITDA | -162.20K | -207.40K | -393.30K | -502.20K | -710.10K |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.03 |
| Normalized Basic EPS | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.02 | -0.02 | -0.04 |
| Normalized Diluted EPS | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 216.00M | 216.00M | 216.00M | 216.00M | 216.00M |
| Average Diluted Shares Outstanding | 216.00M | 216.00M | 216.00M | 216.00M | 216.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |